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Nitric oxide (NO) is a pleiotropic janus-faced molecule synthesized by nitric oxide
synthases (NOS) which plays a critical role in a number of physiological and
pathological processes in humans. The physiological roles of NO depend on its
local concentrations, as well as its availability and the nature of downstream target
molecules. Its double-edged sword action has been linked to neurodegenerative
disorders. Excessive NO production, as the evoked by inflammatory signals, has
been identified as one of the major causative reasons for the pathogenesis
of several neurodegenerative diseases. Moreover, excessive NO synthesis under
neuroinflammation leads to the formation of reactive nitrogen species and neuronal
cell death. There is an intimate relation between microglial activation, NO and
neuroinflammation in the human brain. The role of NO in neuroinflammation has been
defined in animal models where this neurotransmitter can modulate the inflammatory
process acting on key regulatory pathways, such as those associated with excitotoxicity
processes induced by glutamate accumulation and microglial activation. Activated
glia express inducible NOS and produce NO that triggers calcium mobilization
from the endoplasmic reticulum, activating the release of vesicular glutamate from
astroglial cells resulting in neuronal death. This change in microglia potentially
contributes to the increased age-associated susceptibility and neurodegeneration. In
the current review, information is provided about the role of NO, glial activation
and age-related processes in the central nervous system (CNS) that may be
helpful in the isolation of new therapeutic targets for aging and neurodegenerative
diseases.
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Abbreviations: AD, Alzheimer’s disease; BBB, blood-brain barrier; cGMP, guanosine 3′,5′-cyclic monophosphate; CNS, central
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Introduction
Nitric oxide (NO) was discovered as an endothelium-derived
relaxing factor more than two decades ago, and since then,
its participation in a widening number of pathways has been
continuously reported. There is increasing evidence showing that
alterations in the NO signaling may be related with different
diseases as it plays a key role in diverse neurodegenerative-
associated processes such as neuronal death, necrosis, apoptosis
and autophagy (Calabrese et al., 2007). In particular, it
has been suggested that S-nitrosylation is involved in the
pathogenesis of various neurodegenerative disorders including
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS),
multiple sclerosis (MS) and Alzheimer’s disease (AD). The
neuroinflammation that characterize these pathologies is largely
associated with the production of NO; it is the aim of this review
to describe how these NO-induced outcomes are produced,
as well as trying to explain why they are important in the
context of neurodegeneration. Further understanding of how
imbalanced NO metabolism can contribute to neuronal cell
death is determinant to formulate achievable strategies for
the prevention and treatment of neurodegenerative disorders.
Moreover, as NO acts as a double-edged sword contributing
both positively and negatively, or even simultaneously, to these
diseases it is important to disentangle the effects of this molecule
in order to attempt rational interventions towards them.
NO Signaling Pathways
In mammals, NO is mainly synthesized by nitric oxide synthases
(NOS) through the conversion of L-arginine to NO and
L-citrulline (Knowles and Moncada, 1994). Traditionally, three
isoforms of NOS have been identified in central nervous system
(CNS): NOS1 or neuronal NOS (nNOS), NOS2 or inducible
NOS (iNOS) and NOS3 or endothelial NOS (eNOS; Alderton
et al., 2001). These three isoforms differs in their activity patterns:
(i) nNOS localizes to synaptic spines, astrocytes and the loose
connective tissue surrounding blood vessels in the brain; (ii)
iNOS is a calcium (Ca2+)-independent isoform not constitutively
expressed by astrocytes and microglia but these glial cells
often expressed this isoform in pathological conditions such
in response to inflammatory stimuli (Saha and Pahan, 2006);
and (iii) eNOS is present in both cerebral vascular endothelial
cells and in motor neurons (Estévez et al., 1998). The activity
of iNOS is tightly associated with its expression levels and is
induced during cell inflammatory response while nNOS and
eNOS activities depend on intracellular Ca2+ levels and their
CNS expression.
To date, soluble guanylyl cyclase (sGC) is the most accepted
physiological receptor described for NO. This receptor is formed
by α and β subunits together with a prosthetic heme group with
a ferrous iron. The binding of NO to this receptor activates the
C-terminal catalytic domain, which produces guanosine 3′,5′-
cyclic monophosphate (cGMP; Stamler et al., 1997). This enzyme
activity is critically affected by redox status as the oxidation of
the heme moiety on the β-subunit turns the enzyme sensitive
to NO. There are other mechanisms by which oxidative stress
may compromise this cGMP synthetic pathway (Figure 1).
For instance, reactive oxidant peroxynitrite (ONOO−) induced
by NO in the presence of superoxide (O2−) results in a
dysfunctional uncouple variety of NOS that produces O2− rather
than NO under oxidative stress (Xia et al., 1998; Sasaki et al.,
2008).
In response to NO, sGC activity increases more than 200
fold. The increased level of cGMP activates selected pathways
to induce cellular responses (Stamler et al., 2001). Briefly, the
cGMP produced by NO-activated sGC directly interacts with its
downstream effectors, such as cGMP dependent kinase (cGKI
or PKG), cyclic nucleotide gated (CNG) channels and cGMP
dependent phosphodiesterase (PDEs). There is great scientific
agreement about the nNOS and eNOS implication in NO
production in skeletal and cardiac muscle (Kobzik et al., 1994;
Sartoretto et al., 2011). This endogenously produced NO can
promote two physiological functions differentiated by its cGMP-
dependence: (i) to induce relaxation through the cGMP signaling
pathway (Balligand et al., 1993; Mohan et al., 1996); and (ii)
to modulate increases in contraction independent of cGMP
concentration (Kobzik et al., 1994). The activation of such
elements is the preferred mechanism by which NO mediates
most of its physiological effects including vascular smooth
muscle tone and motility, phototransduction and maintaining
fluid and electrolyte homeostasis (Palmer et al., 1987; Bredt et al.,
1990; Knowles and Moncada, 1994).
However, emerging evidence suggests the participation of
NO in another signaling mechanism: ‘‘S-nitrosylation’’ of target
proteins. S-nitrosylation is a non-enzymatic post-translational
modification consisting in a covalent addition of a NO
group to a cysteine thiol/sulfhydryl (RSH). This S-nitrosylation
participates in a huge number of physiological events including
those implicated in muscular contraction (Xu et al., 1998),
cellular trafficking (Ozawa et al., 2008), circulation (Singel and
Stamler, 2005) and apoptotic pathways (Benhar et al., 2008;
Cho et al., 2009). Coherent with this, a main implication of
ryanodine receptor 1 (RyR1) has been found in the activation
and S-nitrosylation of Ca2+ release channel in sarcoplasmic
reticulum of skeletal muscle by low concentration of NO (Eu
et al., 2000).
Based on these studies, a possible involvement of
S-nitrosylation in neuronal function has been suggested in
the brain, particularly in the cerebellar Purkinje cell layer and
dentate gyrus where RyR1 messenger RNA (mRNA) is mostly
prominent (Mori et al., 2000). However, more studies have to
be performed to corroborate a preponderant S-nitrosylation
pathway in CNS and its implication in neuroinflammatory
processes and neurological disorders.
Neuroinflammation and Nitric Oxide
Neuroinflammation represents the coordinated cellular response
to tissue damage and is characterized by the microglial release of
pro-inflammatory factors such as cytokines, proteases and toxic
free radicals. The progress associated with neuroinflammation
can be acute or chronic, while the appropriate regulation
of this general process facilitates recovery, uncontrolled
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FIGURE 1 | Nitric oxide signaling pathway. Figure shows different
steps in the NO signaling cascade and its interaction with several
elements involved in the signaling pathway. NO is synthetized by two
Ca2+-dependent or one independent Ca2+-mediated processes. First, (1)
NOS1 or neuronal NOS (nNOS)-catalyzed reaction converts L-arginine
into L-citrulline in the presence of O2, nicotinamide adenine dinucleotide
phosphate (NADPH) and tertiary-butyl hydroperoxide (TBH) after the
activation of the NMDA receptor by Ca2+. Also, (2) intracellular Ca2+
activates eNOS to release NO from brain microvessels. This NO binds to
soluble guanylyl cylclase (sGC) receptors, which trigger a
cGMP-dependent pathway and interacts with its downstream effectors
(cGKI, CNG, PKG, PDE), the ultimate mediators of the NO’s physiological
response. In addition, sGC is also critically affected by redox status. NO
initiates the synthesis of ONOO− when O2− is present, which results in a
dysfunctional uncouple variety of nitric oxide synthases (NOS) that
produces O2− rather than NO. Finally, (3) NO is synthesized following the
transcriptional expression of a Ca2+-independent iNOS isoform in glial
cells, astrocytes and microglia after cytokine exposure.
neuroinflammation can induce a secondary injury. The main
purpose of acute neuroinflammation is to remove the source
of harm in order to restore the brain to a healthy condition.
However, a maintained response is known to induce neuronal
dysfunction and death (McGeer et al., 2003).
Neuroinflammation has been demonstrated to be closely
associated with the pathogenesis of several psychiatric illnesses
and neurodegenerative diseases like AD, PD and Huntington’s
disease (Bales et al., 2000; Hunot and Hirsch, 2003; Doorduin
et al., 2009; Silvestroni et al., 2009; Dobos et al., 2010;
Rao et al., 2010). Moreover, there is evidence showing that
this condition is detectable years before significant loss of
neurons occurs (Frank-Cannon et al., 2009; Fuhrmann et al.,
2010; Ratai et al., 2011), hence its relevance in the context
of neurodegenerative disorders. This paradigm is supported
by several studies showing that a long-term treatment with
Non-steroidal anti-inflammatory drugs (NSAIDs) may have a
preventative effect in neurodegenerative diseases as the above
mentioned (McGeer and McGeer, 2007; Wahner et al., 2007).
Neuroinflammation-induced cell death is often derived from
the long-term impact caused by the increase of reactive oxygen
and nitrogen species (RONS), which play a major role in
eliciting apoptotic cell death through irreversible oxidative
or nitrosative injury to neuronal elements (Nakagawa and
Yokozawa, 2002). The brain is highly susceptible to oxidative
stress due to its imbalance between an efficient antioxidant
defense system and its capacity to generate oxidative species.
As a matter of fact, the brain presents low levels of glutathione
(GSH) and moderate activity of the antioxidant enzymes
catalase, superoxide dismutases (SODs) and GSH peroxidase.
On the contrary, the elevated levels of ascorbic acid, the high
concentration of transition metals such as copper and iron, and
the huge aerobic metabolism contribute to the generation of
oxidative (ROS/RNS) species eliciting necrotic neuronal death
(Figure 2).
There is an intimate relation between glial activation and
neuroinflammation in the human brain. The presence of
activated microglia was initially considered as a sensitive marker
to identify potential sites of tissue destruction (Mosley et al.,
2006; Galea et al., 2007). Even more, the engagement of astrocytes
and endothelial cells, the observed activation of microglia and its
implication in neuroinflammatory processes, have been widely
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FIGURE 2 | Mechanisms through which ROS/RNS cause apoptosis.
NO can induce oxidative and nitrosative stress, which activates mitochondrial
apoptosis by several pathways, including: (i) stimulation of mitochondrial
permeability transition (MPT); (ii) up-regulation of p53; (iii) activation of the p38
MAP kinase pathway; and (iv) induction of endoplasmic reticulum stress (ERS).
All these processes produce cytochrome c release and apoptosis.
demonstrated to derive from the affection of neuronal viability
through a persistent RONS generation.
The role of NO in neuroinflammation has been determined
in animal models associated with excitotoxicity processes
induced by glutamate accumulation and microglial activation.
Released NO from activated microglia acts at the presynaptic
site blocking the reuptake of glutamate, thus inducing the
activation of N-Methyl-D-aspartate (NMDA) receptors and
facilitating neuronal death (Rao et al., 2007, 2012; Kim et al.,
2009). The regulation of iNOS isoform, highly implicated
in neuroinflammatory processes associated with glial cells,
takes place at the transcriptional level. Several transcription
factors are implicated in trans-activation of iNOS gene, among
them the nuclear factor k-light-chain-enhancer of activated
B cells (NF-κB) is the most important one. Without the
inhibition from the NF-κB p50:p65 arresting protein (IκB)
NF-κB translocates to the nucleus and binds κB elements in
iNOS promoter (Davis et al., 2005; Kanarek et al., 2010).
In glial cells, this NF-κB-mediated iNOS expression triggers
several pathways related with RONS formation, caspase and
nNOS signaling activity and mevalonate production. It has been
demonstrated that chronic NMDA administration up-regulates
the levels of proinflammatory IL-1β, TNF-α, glial fibrillary acidic
protein (GFAP) and iNOS in rat brains (Chang et al., 2008).
Altogether these findings suggest that there is cross-talk between
neuroinflammation and excitotoxicity that involves NO release
and iNOS up-regulation in the brain.
However, it seems clear that NO modulation of inflammatory
processes requires other mechanisms besides microglial cytokine
release. The interaction with key regulatory pathways might be
one of these mechanisms. Coherently, it is known that NO
inhibits NF-κB activation thus controlling inflammation both
in muscular cell lines (Hattori et al., 2004) and through release
by nitrooxyphenyl acetylsalicylate (NO-ASA), a non-steroidal
anti-inflammatory drug (NO-NSAID) in cancer cell lines (Kashfi
and Rigas, 2005). Moreover, S-nitrosylation of NF-κB protein
was the mechanistic role for NO-action resulting in diminished
binding of this protein to DNA for transcriptional activation
(Chattopadhyay et al., 2010).
Historically, astrocytes function in CNS injuries was reduced
to maintain ionic homeostasis and participate in glial scar
formation and tissue repair, which limits inflammation and
promotes tissue repair, secreting nerve growth factors (Simard
and Nedergaard, 2004). However, since NO and IL-1β are also
produced by activated astrocytes, recent studies support an
important active role of these cells in neuroinflammation and
the neurodegeneration associated with dysregulations in NF-κB
pathway and in NO production. Both dysregulations associates
with a crosstalk between lipid mediators, such as sphingosin, and
signaling inflammatory cytokines (Spiegel and Milstien, 2011).
Nitric Oxide and Neurodegenerative
Diseases
Selective neuronal death is typical of most neurodegenerative
diseases including PD, AD, ALS and MS (Guix et al., 2005). The
participation of oxidative stress in the development of several
neurodegenerative disorders has been largely documented
(Calabrese et al., 2007), with NO suggested as a starring character
(Chabrier et al., 1999). This relationship was evidenced by the
fact that increased nitration of protein aggregates was prominent
in different synucleinopathies and tauopathies (Duda et al., 2000;
Horiguchi et al., 2003).
The augmented nitration of proteins can be initiated by an
increase in the production of NO during neuroinflammation and
the generation of free radicals by dysfunctional mitochondria,
which are commonly observed in various neurodegenerative
disorders (Guix et al., 2005; Pacher et al., 2007). Moreover, it
has been demonstrated that NO is able to activate molecular
elements, such as cyclooxygenase (COX; Mollace et al., 2005),
which is typically up-regulated in brain cells under inflammatory
conditions (Mancuso et al., 2007). In addition, the combination
of NO and free radicals like the superoxide anion will result in the
formation of highly reactive peroxynitrite. Peroxynitrite can then
nitrate tyrosine residues on proteins to 3-nitrotyrosine, induce
lipid peroxidation, and cause DNA damage (Ischiropoulos and
Beckman, 2003).
NO is especially harmful under pathological conditions
involving the production of RONS (Wahner et al., 2007)
and ONOO– formation. Nitrotyrosination inhibits tyrosine
phosphorylation and hence affects the signal transduction
pathways of growth factor (Jonnala and Buccafusco, 2001).
Moreover, the presence of nitrotyrosination has been described
in several neurodegenerative diseases linked to oxidative stress,
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such as AD (Guix et al., 2012), PD (Good et al., 1998) and ALS
(Cookson and Shaw, 1999; Smith and Lassmann, 2002).
In sum, diverse stimuli ranging from neuronal impaired
pathway-associated products to environmental toxins can trigger
glial dysregulations. In neurodegenerative diseases, alterations
derived from overactivated glia, microglia and astroglia are
particularly present.
Alzheimer’s Disease
The accumulation of β amyloid (Aβ) plaques and neurofibrillary
tangles are the histopathological gold-standard hallmark for
AD diagnosis. Together with these, the contribution of
neuroinflammatory processes to the aging brain and the
development of Alzheimer’s and other neurodegenerative
diseases is also well documented (Zhang et al., 2013; Mosher and
Wyss-Coray, 2014). However, the exact mechanism by which
microglial activation is disturbed in AD is still not completely
understood.
Accordingly, a critical role of NO in the development of AD
has been suggested, as neuronal cell loss, neuronal injury and
protein misfolding are reported to occur as a consequence of NO
overproduction (Nunomura et al., 2001; Nakamura and Lipton,
2011; Swerdlow, 2011). Significantly, nitrated form of protein tau
has been reported in NFTs and neuritic plaques in brains of AD
patients as well (Reynolds et al., 2006).
There is evidence that link NO production with
mitochondrial dysfunction and neuroinflammation, especially
as regards glial response (Jekabsone et al., 2007). Moreover
the pro-inflammatory and toxic effects of amyloid in neurons
co-cultured with glia are hampered by iNOS inhibitors (Brown,
2007).
Furthermore, it has been suggested that microglial
nicotinamide adenine dinucleotide phosphate (NAPDH)
oxidase complex is the major source of ROS in the brain
(Wilkinson and Landreth, 2006).
The imbalance produced by the detoxification of ROS
prompts an increase in oxidative stress that has proved to be
involved in several excitotoxicity processes (Ferrer et al., 2010).
S-nitrosylation has also been implicated in AD (Lipton et al.,
1993), exhibiting a modulatory effect on glutamatergic NMDA
receptors (Lipton, 2007b). Over-stimulation of NMDA receptors
may produce an excessive Ca2+ influx that can generate ROS and
activate excitotoxicity processes that lead to cell death. Moreover,
this excitotoxicity that has been suggested as a mediator of
neurotoxicity in this neurodegenerative disorder (Lipton, 2007a),
and specifically in neurons, may also activate nNOS and induce
NO overproduction (Gu et al., 2010; Figure 3).
Studies in cell cultures suggest that glutamate-induced cell
death after NO release and ROS results from the inhibition of
mitochondrial respiration caused by glial activation (Beckman
et al., 1994; Loihl and Murphy, 1998; Bal-Price and Brown, 2001).
Interestingly, Aβ stimulates the production of NO, which turns
to be also a proinflammatory marker of microglial activation.
There is evidence of an interaction between Aβ aggregates and
microglia, as it was demonstrated that the later binds to the
former through membrane receptors such as TLR2, 4, 6, and
9 (Bamberger et al., 2003), and this has been suggested as
FIGURE 3 | Central role of amyloid β-peptide (Aβ) in the oxidative
stress elements involved in Alzheimer’s disease (AD). Accumulation of
Aβ plaques results in oxidative stress. This oxidative stress might result from
the implication of different pathways, such as mithocondrial dysfunction or
inflammatory response, and it is manifested by synaptic damage and
alterations in Ca2+ homeostasis. This may lead to apoptotic processes that
result in the death of the cell and neurotoxicity. This is consistent with the
concept of Aβ-associated oxidative stress and neurodegeneration in AD brain.
a constituent of the inflammatory process in this disease. In
addition, there is evidence of Nod-like receptor (NLR) family,
pyrin domain containing 3 (NLRP3), activation in a mouse
model of AD (Lambert et al., 2009). Interestingly, NLRP3
is a modulator of IL-1β, a proinflammatory cytokine which
production is also stimulated by the presence of Aβ plaques,
together with other inflammatory markers, including IL-6 and
tumor necrosis factor alpha (TNF-α; Jekabsone et al., 2006;
Jimenez et al., 2008).
The description of the mechanism by which Aβ increases
the production of NO is still incomplete. One explanation is
that progressive Aβ accumulation disrupts the Ca2+ homeostasis
causing the before mentioned rises in NO (Cetin et al., 2013).
Also, an increase of lipid peroxidation in the cellular membrane
has been observed in the presence of Aβ accumulation (Xie et al.,
2010). Another source of Aβ-induced increase in oxidative stress
is the known interaction between both APP and amyloid plaques
with mitochondrial proteins, which leads to alterations in normal
function (Spuch et al., 2012).
Nitrosative stress has also been associated with pathological
alterations (Nakamura and Lipton, 2011) since this process
increases the aggregation of Aβ in early stages of AD, impairing
the formation of hippocampal long-term potentiation (LTP;
Kummer et al., 2011; Thiabaud et al., 2013). In addition,
increasing oxidative stress in cultured hippocampal neurons
led to nitrotyrosination of presenilin protein (PSEN1), which
finally induced an enhancement of total Aβ (Guix et al.,
2012). Interestingly, AD brains show similar increased levels
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of nitrotyrosinated PSEN1 in comparison with age-matched
controls (Guix et al., 2012), which remarks the relevance of
oxidative stress to the neuroinflammatory process and the
progress of pathophysiological hallmarks in this disease.
Parkinson’s Disease
PD is an age-related neurodegenerative disease characterized by
a prominent loss of dopaminergic neurons in the substantia nigra
(SN; Dauer and Przedborski, 2003; Danielson and Andersen,
2008). The loss of DA modulation triggers a complex series of
neurochemical, anatomical, and electrophysiological alterations
that lead to persistent changes in striatal neurons and their
signaling pathways (Wang and Pickel, 2002; Bamford et al.,
2004; Picconi et al., 2004). Significant evidence indicates that
chronic inflammatory response, mainly triggered by activated
microglia and astroglia has a crucial role among the pathogenic
mechanisms contributive to degeneration of dopaminergic
neurons (McGeer et al., 1988, 2003; Barcia et al., 2004; Benner
et al., 2008).
As in AD, the NO-induced glial activation has also a
detrimental effect related to PD. The pathophysiology of
microglial activation due to increases in oxidative stress causes
an increased uptake of manganese inside the cell, which has been
linked to the density of microglial cells especially in the basal
ganglia (Gonzalez-Cuyar et al., 2014).
Substantial evidence demonstrates the involvement of NO in
the degeneration of dopaminergic neurons in the SNpc (Jenner,
2003) and along the nigrostriatal pathway (Duncan and Heales,
2005; Zhang et al., 2006). It has also been demonstrated that
nitrotyrosination can inhibit tyrosine hydroxylase (Kuhn and
Geddes, 2002), and it is known that monoamine oxidase B
(MAO-B) generates H2O2 during the catecholamine metabolism
(Tipton, 1967). This is interesting because the activity of MAO-B,
which is located in the mitochondrial membrane, is increased in
aged population (Bhaskaran and Radha, 1983). This source of
increased oxidative stress has been suggested as a risk factor for
the development of PD (Jenner, 2003).
Neuroinflammation can be induced by several factors,
such as exposure to either infectious agents or toxicants.
Compounds with such proinflammatory characteristics have
been recognized from some time now as significant contributors
to the pathogenesis of PD. This is coherent with studies showing
that the inhibition of complex I of the mitochondrial electron
transport by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) can cause human parkinsonism, and increased
nitrotyrosine in Lewy bodies and oxidative damage (Beal, 1998,
2002). Moreover, rotenone, a widely used pesticide, has proved
to cause a syndrome in rats that mimics typical pathology
displayed by PD patients (He et al., 2003), including microglial
activation and the presence of proinflammatory markers in the
brain (Li et al., 2012).
A potential role of NO and NOS isoforms in the
pathophysiology of PD has been emphasized. Increases in iNOS
expression and NO-mediated modulation of the mitochondrial
apoptotic pathway have also been observed after injection of
lipopolysaccharide (LPS) or 6-OHDA in the SN and striatum
in different experimental models of PD (Singh et al., 2005). It is
worth mentioning that nNOS overexpression and the formation
of peroxynitrite in polymorphonuclear leukocytes have been
reported in PD patients (Gatto et al., 2000; Gilgun-Sherki
et al., 2001). Interestingly, this peroxynitrite exposure has been
also linked to the formation of α-synuclein aggregates (Souza
et al., 2000). This is important, given that nitrated α-synuclein
seems to contribute to the increased ROS production, decreased
adenosine triphosphate (ATP) production, and degeneration
of dopaminergic neurons, as well as to microglial activation,
a reduction in the number of T-cells and increased cell death
(Murray et al., 2003; Guix et al., 2005; Figure 4).
However, regardless all these data, the exact contribution
of NO-dependent mechanisms to neurodegeneration and
neuroinflammation in PD is still not completely understood.
One of the proposed ideas is the production of ROS during the
normal metabolism of dopamine (DA). In the human SNpc, the
oxidation product of DA may polymerize to form neuromelanin,
which has proved effective in aggravating the degenerative
process through neuroinflammation (Zecca et al., 2008). On the
other hand, although data from preclinical and clinical studies
suggest that neuroinflammation could be a hallmark of the
progression of the disease from an early asymptomatic stage
(Lee et al., 2009). An elevated level of inflammatory cytokines,
such as TNF-α and IL-6 NO-associated (Wilms et al., 2007) was
found in the post mortem brain of PD patients. Importantly,
an up-regulation of the genes encoding for these inflammatory
cytokines, COX-2 and iNOS was observed in microglial cells
from PD patients (Knott et al., 2000; Saha and Pahan, 2006). In
sum, although later studies have shed light on the etiopathology
and neuroinflammatory processes associated with PD, more
studies are have to be developed since the exact mechanism
through which neuroinflammation and NO-associated pathways
contribute to the development or progress of PD remains
elusive.
Interestingly, the S-nitrosylation of parkin, another element
significantly implicated in familial form of PD, has shown to
interfere with the protective properties of this protein. Briefly,
parkin acts as a transcriptional repressor of p53 (da Costa et al.,
2009). What various studies demonstrate is that the presence
of oxidative stress in the form of S-nitrosylation diminishes
parkin’s protective features (Chung et al., 2004; Sunico et al.,
2013). Concretely, the addition of ubiquitin on specific substrates
that parkin provides is impaired in the presence of NO. This
evidence suggests that S-nitrosylation is directly implicated in the
pathophysiology of PD by impairing the protective role of parkin.
Multiple Sclerosis
MS is an inflammatory disease in which the insulating myelin
of SNC is damaged (Duncan and Heales, 2005). Of unknown
etiology, this disease is characterized by an infiltration of
inflammatory mononuclear cells into the CNS through a
damaged blood-brain barrier (BBB), which causes the release
of inflammatory and cytotoxic mediators, including NO (Smith
and Lassmann, 2002). This neuroinflammation elicits the
infiltration of T lymphocytes, the recruitment of macrophages,
astrocytic damage and the local activation of microglia (Gay
et al., 1997; Niki´c et al., 2011). Although there is a strong
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FIGURE 4 | Neuroinflammation in Parkinson’s disease (PD). Different
genetic and/or environmental factors such as parkin mutations or MTPT
exposure lead to the accumulation of α-synuclein aggregates in the brain.
This accumulation triggers the activation of glial cells. The proinflammatory
cytokines freed by astrocytes and microglia stimulate the release of several
neuroinflammatory markers, including NO, IL-6, IL-1β, and TNF-α, which
can promote neuronal death and aggravate the neurodegenerative
process.
correlation between neuroinflammation and axonal damage,
the exact mechanism of this damage has to be elucidated
(Figure 5).
Importantly, since NO expression participates in the
homeostatic maintenance of the BBB permeability, this molecule
may have an essential role in MS. Additionally in this BBB
breakdown different pathways might be involved inducing
oligodendrocyte injury and loss of neuronal function (Smith
and Lassmann, 2002). Although there is considerable evidence
showing that the three NOS isoforms are involved in the
pathophysiology of MS (Wu and Tsirka, 2009; AlFadhli
et al., 2013), iNOS would play, together with cyclic guanosine
monophosphate (Janigro et al., 1994; Hurst and Fritz, 1996;
Mayhan, 1999) and the overproduction of RNS (Mayhan, 1999;
Kean et al., 2000; Spitsin et al., 2000; Winkler et al., 2001),
a particularly crucial role specially at the beginning of this
disease (Duncan and Heales, 2005).
The first direct evidence of glial implication in this disease
was the demonstration of an altered mitochondrial function,
following the inhibition of microglial respiratory chain in
an animal model of demyelination (Zielasek et al., 1995;
Lu et al., 2000). In these studies, a tendency for impaired
Nicotinamide adenine dinucleotide (NADH) dehydrogenase
activity and a compensatory increase in cytochrome oxidase
in chronic active MS plaques was also demonstrated.
More recently, another role of microglia in MS has been
clarified since the phagocytosis of neuronal debris, the
result of neuronal and axonal damage, would contribute to
ongoing neurodegeneration in this disease (Huizinga et al.,
2012).
Initially, astrocytes have been assigned a secondary role in the
lesion formation and repair in MS. However, recent literature
has implicated astrocytes in both lesion development and repair
depending on the lesion stage and topography (Brosnan et al.,
1994). Additionally, increased iNOS and mRNA has been
identified in astrocytes in post mortem studies (Bagasra et al.,
1995), and the MS-associated characteristic of reversible axonal
conduction blockade has also been demonstrated in in vitro
conditions (Redford et al., 1997). However, iNOS reactivity in
hypertrophic astrocytes has only been described in acute but
not chronic MS lesions (Brosnan et al., 1994; Liu et al., 2001)
associated with peroxynitrite overproduction. More recently,
different studies have shown the contribution of brain-derived
neurotrophic factor (BNDF)-dependent NO release (Colombo
et al., 2012) and the NF-κB pathway associated with NO
production and astrocytes activation to the regulation of cytokine
and chemokine expression. Interestingly, both markers have
been related to the regulation of the severity and progression of
the disease (Brambilla et al., 2009).
Another crucial step for the recruitment of leukocytes to the
CNS and evolution of MS pathology is the chemokine expression
by microglia and macrophages. Associated with this expression
and in response to interleukin release astrocytes are able to
regulate the production of different chemokines such as C-X-C
motif chemokine 12 (CXCL12; Calderon et al., 2006). Recently
it was demonstrated that the excessive expression of iNOS is
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FIGURE 5 | Inflammation in multiple sclerosis (MS). Immune T-cells
bypassing the blood-brain barrier (BBB) affect oligodendrocyte structure
and activate glial response through NF-κB and AP-1. Reactive oxygen
species (ROS) and nitric oxide (NO) secretion by activated microglia and
astrocytes further contribute to myelin damage, axon degradation, and
ultimate neuronal death.
able to decrease the expression level of CXCL12 gene, which has
been implicated in the restriction of immune cell invasion to
the CNS and the neuroinflammation limit in animal model of
MS (Petkovi´c et al., 2013). This suggests that down-regulating
NO release and maintaining CXCL12 expression within the CNS
could be a potential therapeutic approach to MS.
Amyotrophic Lateral Sclerosis
ALS is mainly characterized by a progressive degeneration of
motor neurons in the CNS that results in weakness, paralysis, and
death (Long and Nguyen, 2013). The exact mechanism triggering
this disorder is not totally understood, but within the primary
hypotheses put forth to explain motor neuron degeneration,
oxidative stress counts among the preferred theories (Rothstein,
2009).
There is evidence in mouse models of ALS that the
administration of non-selective NOS inhibitors reduces motor
neuron degeneration (Hyun et al., 2003). Accordingly, post
mortem examinations of brains from patients with ALS show
high levels of NO metabolites (Boll et al., 2003), together with
clear protein and DNA damage caused by oxidation (Agar and
Durham, 2003; Kato et al., 2005).
Another line of evidence proposes astroglial cells,
specifically astrocytes, as the primary generator of NO-
derived molecules contributing to both ALS initiation and
development (Pehar et al., 2006; D’Amico et al., 2013).
In this sense, some evidence demonstrates that astrocytes
exposed to NO promote apoptosis of embryonic motor
neurons (Cassina et al., 2002). Moreover, peroxynitrite has
proved to also affect protein activity by oxidizing amino
acid residues, as seen in nitrotyrosine, which is found in the
CNS of both ALS patients (Abe et al., 1997; Bruijn et al.,
1997) and ALS-mice models (Casoni et al., 2005; Yoshino
and Kimura, 2006). Hence, peroxynitrite-mediated tyrosine
nitration has been suggested as key for triggering neuronal
degeneration in ALS (Beckman and Crow, 1993; Peluffo et al.,
2004).
In addition, one of the genetic features found in more than
20% of ALS patients is an alteration in the gene encoding
for the enzyme SOD-1, an intrinsic antioxidant (Reaume
et al., 1996). Studies in vitro show that, differently from the
augmentation in NO release found in normal SOD-1, mutant
cells for this gene express fewer levels of NO (Cookson
et al., 2002). This is coherent with the evidence indicating
an association of this gene with the familial form of ALS
(Conwit, 2006). Interestingly, the reaction of ONOO– with
the mutant form of SOD-1 has shown to have an effect on
protein nitrotyrosination (Beckman and Crow, 1993), which is
coherent with data obtained from clinical studies (Abe et al.,
1995).
Together, all these data support the idea of a prominent role
of oxidative harm as one of the principal cellular mechanisms
of motor neuron degeneration (Beckman and Esteves, 2006;
Figure 6).
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FIGURE 6 | Glial-induced neuroinflammation and neurotoxicity in
amyotrophic lateral sclerosis (ALS). Reactive astrocytes contribute to the
degenerative process by influencing the activity of microglial and immune
cells. An up-regulation of filament glial fibrillary acidic protein (GFAP) takes
place and astrocytes increase the release of proinflammatory markers
including NO and ROS. When mutated SOD1 accumulates within microglia,
the later generates substances potentially harmful to other cells, thus
potentiating neurotoxicity. Demyelinization and progressive loss of cholesterol
is also observed after oligodendrocyte damage. These glial cells show a
reduction in the monocarboxylate transporter 1 (MCT1), which in turn difficult
the energy supplies to the neuron.
Conclusions and Perspectives
NO plays multiple roles in the nervous system and glial
regulated pathways associated with neuroinflammation and
neurodegenerative diseases. Under physiological conditions,
it contributes to regulating proliferation, survival, and
differentiation of neurons. It is involved in synaptic activity,
neural plasticity, and cognitive function (i.e., memory); it also
exerts long-lasting effects through regulation of transcription
factors and modulation of gene expression. However, RNS
generation also brings modifications to critical cysteine residues
in proteins, including Snitrosylation or nitrotyrosination.
If the physiological control of this signaling pathway fails, the
pathological effects of NO and other RNS lead to (or are involved
in) neuroinflammation and neurodegeneration processes. The
NO-associated products resulted from the activation of glial
response (either astrocyte or microglia) appear to especially
contribute to the excitotoxic process that leads to neuronal
death in several pathologies. More concretely, neurons appear
particularly vulnerable to the effects of nitrosative stress.
Susceptibility to NO and peroxynitrite exposure may depend on
factors such as the intracellular antioxidants and stress resistance
signaling pathways. Thus, NO redox signaling and modulation
of the adaptive cellular stress responses, being released by glial
cells or activating them, require further research to develop
predictive means to deal with the increasing number of age-
related neuropathological conditions.
Collectively, among NOS isoforms implicated in glial
response related with neurodegenerative diseases, nNOS is
the most implicated in a wide range of functions and
pathologies with pleiotropic effects. In view of its ubiquitous
expression in the CNS, there are extensive and unique chances
for nNOS to interact with other neuronal elements, such
as microglial and astroglial cells, thus exerting appropriate
functional properties. Given increased nNOS activity and
expression in many diseases, inhibiting nNOS might have
putative therapeutic effects, among which anti-inflammatory
properties can be hypothesized. Unfortunately, it will be
a preferable means to interfere with specific pathway, for
example, uncoupling nNOS–PSD95 interactions (Cao et al.,
2005) since to date is impossible to inhibit nNOS directly
without disturbing vital physiological functions and produce side
effects.
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